Karteolol |
| (IUPAC) ime |
|---|
| (RS)-5-[3-(tert-butilamino)-2-hidroksipropoksi]-3,4-dihidrohinolin-2(1H)-on |
| Klinički podaci |
|---|
| Robne marke | Ocupress |
|---|
| AHFS/Drugs.com | Mikromedeks, detaljne potrošačke informacije |
|---|
| MedlinePlus | a601078 |
|---|
| Identifikatori |
|---|
| CAS broj | 51781-06-7 |
| ATC kod | C07AA15S01ED05 |
| PubChem[1][2] | 2583 |
| DrugBank | DB00521 |
| ChemSpider[3] | 2485 |
| UNII | 8NF31401XG  Y |
|---|
| KEGG[4] | D07624 Y |
|---|
| ChEBI | CHEBI:3437 Y |
|---|
| ChEMBL[5] | CHEMBL839 Y |
|---|
| Hemijski podaci |
|---|
| Formula | C16H24N2O3 |
| Mol. masa | 292,373 g/mol |
| SMILES | eMolekuli &PubHem |
| InChI |
|---|
InChI=1S/C16H24N2O3/c1-16(2,3)17-9-11(19)10-21-14-6-4-5-13-12(14)7-8-15(20)18-13/h4-6,11,17,19H,7-10H2,1-3H3,(H,18,20) Y
Key: LWAFSWPYPHEXKX-UHFFFAOYSA-N Y |
|
| Farmakokinetički podaci |
|---|
| Bioraspoloživost | 85% |
| Metabolizam | Hepatički, aktivan sa 8-hidrokarteololom |
| Poluvreme eliminacije | 6–8 sati |
| Izlučivanje | Renalno (50-70%) |
| Farmakoinformacioni podaci |
|---|
| Trudnoća | C(US) |
| Pravni status | ℞ Prescription only |
| Način primene | Kapi za oči |
Karteolol - trgovački naziviCartrol,Ocupress,Teoptic,Arteolol,Arteoptic,Calte,Cartéabak,Carteol,Cartéol,Cartrol,Elebloc,Endak,Glauteolol,Mikelan,Poenglaucol,Singlauc - je a neselektivnibeta blokator koji se upotrebljava za liječenjeglaukoma.Ovajbeta-blokator ima unutrašnju simpatomatsku aktivnost. Djelujući nasrčaneβ1- i β2receptore karteolol smanjuje broj otkucaja i kontraktilnost srca za atrio-ventrikularno provođenje signala i aktivnost na relacijiplazma -renin. Stoga je pogodan za liječenjesrčane aritmije iangine.[6]Očni pritisak regulira smanjenjem proizvodnjevodice što ga čini djelotvornim u liječenjuglaukoma.
Tačan mehanizam djelovanja nije poznat.
Lijek je je patentirala kompanijaOtsuka Pharmaceutical,1973. godine.Karteolol dalje smanjujeočni pritisak smanjenjem proizvodnje oristi.
- ↑Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
- ↑Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
- ↑Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
- ↑Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
- ↑Šablon:RömppOnline
- El-Kamel A, Al-Dosari H, Al-Jenoobi F (2006). „Environmentally responsive ophthalmic gel formulation of carteolol hydrochloride.”. Drug Deliv 13 (1): 55–9. DOI:10.1080/10717540500309073. PMID 16401594.
- Kuwahara K, Oizumi N, Fujisawa S, Tanito M, Ohira A (2005). „Carteolol hydrochloride protects human corneal epithelial cells from UVB-induced damage in vitro.”. Cornea 24 (2): 213–20. DOI:10.1097/01.ico.0000141232.41343.9d. PMID 15725891.
- Trinquand C, Romanet J, Nordmann J, Allaire C (2003). „[Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study]”. J Fr Ophtalmol 26 (2): 131–6. PMID 12660585.
- El-Kamel A, Al-Dosari H, Al-Jenoobi F (2006). „Environmentally responsive ophthalmic gel formulation of carteolol hydrochloride.”. Drug Deliv 13 (1): 55–9. DOI:10.1080/10717540500309073. PMID 16401594.
- Kuwahara K, Oizumi N, Fujisawa S, Tanito M, Ohira A (2005). „Carteolol hydrochloride protects human corneal epithelial cells from UVB-induced damage in vitro.”. Cornea 24 (2): 213–20. DOI:10.1097/01.ico.0000141232.41343.9d. PMID 15725891.
- Trinquand C, Romanet J, Nordmann J, Allaire C (2003). „[Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study]”. J Fr Ophtalmol 26 (2): 131–6. PMID 12660585.
